Literature DB >> 627140

Fluoride bioavailability after intravenous and oral administration: importance of renal clearance and urine flow.

J Ekstrand, M Ehrnebo, L O Boréus.   

Abstract

Fluoride (3 mg) was administered as a continous intravenous infusion during 30 min to 6 healthy subjects. Plasma concentrations and urinary excretion of fluoride in these experiments were compared with those obtained following oral administration of 2.82 mg, 4.50 mg, 5.64 mg, and 9.40 mg in the form of tablets and capsules. There were large day-to-day variations in the renal clearance of fluoride. This was shown to be due to differences in the urinary flow, an increase in flow causing an increase in renal clearance. The mean value of renal clearance from all experiments was 66.2 +/- 27.8 (SD; n = 16) ml/min. The extrarenal clearance, suggested to represent mainly the clearance to the bone pool, showed less interindividual variation: mean 110.3 +/- 32.3 (SD; n = 6) ml/min; the fraction remaining in the bone pool was highly consistent: 0.579 +/- 0.049 (SD; n = 6). When apparrent bioavailability was calculated from plasma and from urinary data, there was a great intra- and intersubject variation, as well as poor agreement between the two methods of calculations. This was found to be due to the day-to-day variation in renal clearance, which, in turn, varied with urinary flow. By use of equations that corrected for these variations, it was found that the bioavailability of sodium fluoride tablets is approximately 100%.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 627140     DOI: 10.1002/cpt1978233329

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  What is the future for fluoride in the treatment of osteoporosis?

Authors:  J D Ringe; P J Meunier
Journal:  Osteoporos Int       Date:  1995-03       Impact factor: 4.507

2.  Occupational fluoride exposure and plasma fluoride levels in man.

Authors:  M Ehrnebo; J Ekstrand
Journal:  Int Arch Occup Environ Health       Date:  1986       Impact factor: 3.015

3.  Bioavailability and pharmacokinetics of cimetidine.

Authors:  A Grahnén; C von Bahr; B Lindström; A Rosén
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

4.  A mathematical model for fluoride uptake by the skeleton.

Authors:  C H Turner; G Boivin; P J Meunier
Journal:  Calcif Tissue Int       Date:  1993-02       Impact factor: 4.333

5.  A new and improved gas chromatographic method for the determination of fluoride in plasma and faeces.

Authors:  J H Glerum; A Van Dijk; S W Klein
Journal:  Pharm Weekbl Sci       Date:  1984-04-27

6.  Influence of milk products on fluoride bioavailability in man.

Authors:  J Ekstrand; M Ehrnebo
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

7.  Plasma fluoride concentration and urinary fluoride excretion in obese and non-obese patients following enflurane anesthesia.

Authors:  Y Tohyama
Journal:  J Anesth       Date:  1987-09-01       Impact factor: 2.078

8.  Effect of age on the disposition of sodium fluoride.

Authors:  C Jeandel; F Lapicque; P Netter; B Bannwarth; C Monot; P Gillet; E Payan; M Guillaume; G Cuny
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man.

Authors:  M Ehrnebo; S O Nilsson; L O Boréus
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

10.  Fluoride pharmacokinetics during acid-base balance changes in man.

Authors:  J Ekstrand; M Ehrnebo; G M Whitford; P O Järnberg
Journal:  Eur J Clin Pharmacol       Date:  1980-08       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.